Competition
The Source’s Jaime King Awarded American Antitrust Institute Award
Amy Y. Gu, Managing Editor July 5, 2018
We are excited to announce that The Source’s Executive Editor Jaime S. King has been awarded the Jerry S. Cohen Award by the American Antitrust Institute for her article “The Anti-Competitive Potential of Cross-Market Mergers in Health Care,” which she co-authored with Erin C. Fuse Brown of Georgia State University College of Law. The article won in the “Best Antitrust and Mergers Article” category and discusses the potential for cross-market acquisition to harm competition, and whether existing antitrust laws could support challenges to cross-market acquisitions. The Cohen Award was created in …
Continue Reading Download PDF
The Source Roundup: July 2018 Edition
Source Fellow July 2, 2018
By: Megan O’Leary, Student Fellow Happy July! In this edition of the Source Roundup, we cover six academic articles and reports from May and June. The topics this month include: (1) the drug rebate system, (2) provider-payer integration as model for healthcare reform, (3) anticompetitive behaviors that delay generic drug competition, (4) short-term insurance plan expansion increases 2019 ACA marketplace premiums, and (5) competition concerns of healthcare consolidation. The Drug Rebate System is Not the Villain in Rising Health Care Costs There are plenty of reasons health care price …
Continue Reading Download PDF
Source Advisory Board Member Tim Greaney Offers Policy Recommendations in Healthcare Antitrust White Paper
Amy Y. Gu, Managing Editor June 29, 2018
Source Advisory Board Member Tim Greaney co-authored a two-part white paper with Professor Barak Richman of Duke University for the American Antitrust Institute (AAI) on healthcare competition. In Part I of the series, Greaney and Richman provide an in-depth analysis of consolidation in the markets for delivery and payment of healthcare services by taking a close look at horizontal and vertical mergers in both the provider and insurer markets. The paper identifies major competition concerns brought on by consolidation and suggest further academic and policy research to support more vigorous antitrust enforcement. In Part II, Greaney and …
Continue Reading Download PDF
CVS-Aetna Merger: Competition and Patient Care Concerns Raised at CDI Hearing
Source Fellow June 26, 2018
By: Megan O’Leary, Student Fellow CVS Health and Aetna Insurance defended their proposed vertical merger to the California Department of Insurance (CDI) on June 19. The Source attended the hearing and brings this report regarding the prospects and impact of the planned merger. Pursuant to the California Insurance Code, Commissioner Dave Jones was able to call the public hearing as it involves an Aetna subsidiary based in California. While the commissioner does not have direct approval authority over the merger, his input could have an impact on how other states …
Continue Reading Download PDF
California Legislative Beat: Transformative Healthcare Bills of 2018 (Pt. 1)
Sammy Chang, Health Policy Researcher June 21, 2018
Year two of California’s 2017-2018 legislative session has been an active one. As lawmakers work diligently, The Source will take a brief look at some 2018 bills that can potentially change the California healthcare landscape. SB 1021: This bill removes the sunset provision for AB 339 (2015), which was enacted to cap cost sharing for a covered outpatient prescription drug at $250/$500 per 30-day supply.[1] Furthermore, the bill codifies the regulation that “prohibits an enrollee or insured from being charged more than the retail price for a prescription drug …
Continue Reading Download PDF
Litigation and Enforcement Highlights – June 2018
Amy Y. Gu, Managing Editor June 15, 2018
Pharmaceutical litigation and enforcement actions took the spotlight in the news last month. In this edition, we highlight two high profile enforcement cases and continue to follow the Allergan patent saga. In enforcement, we saw developments in the FTC’s antitrust enforcement against generic drugmaker Impax and the DOJ’s anti-kickback enforcement against brand manufacturer Pfizer. These actions could set important precedents for similar cases and significantly impact price and competition in the pharmaceutical industry. Meanwhile, Allergan continues to defend against attacks of its tribal immunity maneuver in a seemingly losing battle. …
Continue Reading Download PDF
The Source Roundup: June 2018 Edition
Source Fellow June 1, 2018
By: Megan O’Leary, Student Fellow Happy June! In this edition of the Source Roundup, we cover five academic articles and reports from April and May. The topics this month include: 1) barriers for generics to lower specialty drug prices, 2) a call to reform pharmaceutical systems in the United States and Canada, 3) efforts by states to stabilize the individual market, 4) Vermont’s push for community-driven health care reform, and 5) antitrust lawsuits in the pharmaceutical industry. Barriers for Generics to Lower Specialty Drug Prices The Health Affairs article Generic …
Continue Reading Download PDF
California Legislative Beat: Noteworthy 2017 Bills Still Pending That Should be Passed
Sammy Chang, Health Policy Researcher May 24, 2018
As year two of the California legislative session goes into full swing, a couple of bills introduced in 2017 are still active and waiting to be passed. This month’s post will look at four active 2017 bills that should be considered for passage. SB 199: This bill authorizes the creation of an advisory committee to research and develop recommendations on the creation of a database to be titled California Health Care Cost, Quality, and Equity Atlas. This bill is the first step to creating a statewide database that would collect …
Continue Reading Download PDF
Litigation and Enforcement Highlights – May 2018
Amy Y. Gu, Managing Editor May 15, 2018
Several major court decisions were handed down last month that may leave lasting impacts in terms of price and competition in the healthcare industry. Specifically, the 4thCircuit Court of Appeals ruled Maryland’s Price Gouging Law unconstitutional, while the Supreme Court upheld inter partes review, a controversial patent review process. In antitrust enforcement, the Justice Department began its review of the Cigna-Express Scripts merger. 4thCircuit Strikes Down Maryland Price Gouging Law In a significant victory for the pharmaceutical industry, the 4thU.S. Circuit Court of Appeals found Maryland’s landmark 2017 law, …
Continue Reading Download PDF
Litigation and Enforcement Highlights – April 2018
Amy Y. Gu, Managing Editor April 10, 2018
This month we saw increased activity in state and private antitrust litigation. Earlier in April, we blogged about an antitrust lawsuit brought by California’s Attorney General against Sutter Health, accusing the health system of anticompetitive conduct that allegedly drove up healthcare prices across the state. In private antitrust litigation, Blue Cross/Blue Shield suffered a significant blow in a major lawsuit in Alabama federal court, while an Illinois judge ordered plaintiffs in a hospital class action suit to find new representatives. Meanwhile, on the regulatory front, merger mania continued as two additional proposed …
Continue Reading Download PDF